Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. - Wikidata - awgldk - TriplyDB

Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies.

Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies.

http://www.wikidata.org/entity/Q33295304

about

Revisiting the Middle Molecule Hypothesis of Uremic Toxicity: A Systematic Review of Beta 2 Microglobulin Population Kinetics and Large Scale Modeling of Hemodialysis Trials In Silico Biomarkers and Genetics in Peripheral Artery Disease.Peripheral arterial disease in diabetes: is there a role for genetics?Reproducibility of SELDI Spectra Across Time and Laboratories Association of adiponectin with peripheral arterial disease and mortality in nondiabetic hemodialysis patients: Long-term follow-up data of 7 years.No Relationship between Serum and Salivary β2- Microglobulin Levels in A Sample of Adult Diabetic Men with Chronic Kidney Disease without Renal Replacement Therapy.Novel filtration markers as predictors of all-cause and cardiovascular mortality in US adults Peripheral artery disease: current insight into the disease and its diagnosis and management.Novel markers of peripheral arterial disease.Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling The combination of 9p21.3 genotype and biomarker profile improves a peripheral artery disease risk prediction model.The relationship between Helicobacter pylori and beta-2 microglobulin in humans.An update on uremic toxins.Proteomic identification of biomarkers of vascular injury.Human brain arteriovenous malformations express lymphatic-associated genes.β2-microglobulin, cystatin C, and creatinine and risk of symptomatic peripheral artery disease.Association between plasma Beta-2 microglobulin level and cardiac performance in patients with chronic kidney disease.A biomarker panel for peripheral arterial disease.Biomarkers of peripheral arterial disease.Two decades of progress in vascular medicine.The relationship between glycemic control, beta2-microglobulin and inflammation in patients on maintenance dialysis treatment Identification of cysteinylated transthyretin, a predictive biomarker of treatment response to partially hydrolyzed guar gum in type 2 diabetes rats, by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.High levels of serum β2-microglobulin predict severity of coronary artery disease Usefulness of the addition of beta-2-microglobulin, cystatin C and C-reactive protein to an established risk factors model to improve mortality risk prediction in patients undergoing coronary angiography.Genome-wide association study identified the human leukocyte antigen region as a novel locus for plasma beta-2 microglobulin.Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease.Genetics of peripheral artery disease Proteomic Biomarkers of Atherosclerosis.Recent advances in atherosclerosis-based proteomics: new biomarkers and a future perspective.Clinical trials of adult stem cell therapy for peripheral artery disease.Association of Beta-2 Microglobulin with Inflammation and Dislipidemia in High-Flux Membrane Hemodialysis Patients.ß-2 microglobulin level is negatively associated with global left ventricular longitudinal peak systolic strain and left atrial volume index in patients with chronic kidney disease not on dialysis.Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease Stages 3 and 4.Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases.Transcriptional regulation of beta2-microglobulin demonstrated via a novel genomic and proteomic analysis of percutaneously collected peripheral atheroma.A Study on the Relationship between Serum Beta 2-Microglobulin Levels, Underlying Chronic Kidney Disease, and Peripheral Arterial Disease in High-Vascular-Risk Patients.Peripheral artery disease. Part 1: clinical evaluation and noninvasive diagnosis.Developmental conditioning of the vasculature.Role of β2-microglobulin in uremic patients may be greater than originally suspected.Association Between Serum β2 -Microglobulin Levels and Prevalent and Incident Physical Frailty in Community-Dwelling Older Women.

P2860

Q27009538-AA8770AB-2659-4DD4-BD98-6F70997F83EF Q30240841-A236F14C-BC73-4A83-BAC9-097E7CF9A1F2 Q30426617-7D673F85-7F6B-4339-99A6-BE96FEF06833 Q30484977-5523BBFF-FB12-44CB-B07E-5696568CBFAE Q31146255-54A1F9ED-E3BE-46AF-A44E-AA0447665D4B Q33810673-D5618D4B-845D-434C-814A-E6253F78EB0B Q33827728-019FC470-9C64-4570-A1F8-C2070B5884B2 Q33951581-BEC3231F-9044-44BD-93EE-6AB1A0D71A9D Q33984026-9C9DADC7-C2B2-43A5-8F76-D2365C39A9F7 Q34073510-AD9B4D47-61EF-4921-944A-2DC93FC02230 Q34140830-BD36544C-3A52-4ECC-A186-097BA2ECE059 Q34177420-245E8982-3FF1-44FF-9B32-9FAA25249A3A Q34641464-67C68B3F-53EC-4FFC-9456-5A5D79C4FEF9 Q34667425-9255D780-1BE3-4F0E-9B02-F77EE1982454 Q34824758-DBD20C21-BE8C-4FE7-8530-30904B4E70CC Q35026210-256DA5CC-41E0-4933-863C-D3FD6C1EB093 Q35089837-8302A350-C4B3-4691-B1C6-5F22CF6018FB Q35098249-A9577A5B-2E4F-489A-A209-7E52EBF47C01 Q35170187-0BDB6ED6-E1E0-4DC3-B2C3-D7CA2F5E2B8C Q35175641-9A0DDDBD-30DC-4241-8D8B-AE4F007DA1F1 Q35546014-FEFB7662-CC66-4CDA-9EC1-C50A8CDE43F6 Q35900864-CD6B9FFC-02F0-4BC6-91FF-5BB88CA6C94C Q36294507-0F1FC333-AC50-43ED-ACD0-BD0FCAB0A70B Q36675094-14E0E490-6746-4472-B37E-02114FEF7047 Q36849928-6F3C7AA4-52A5-4876-847B-7812D2146A31 Q37097986-0256C460-F3CD-46B8-AD8D-B9F7351FC233 Q37127078-DC55EC7C-949B-4944-A183-8599FD0EA047 Q37207340-C6D40661-F889-4096-8D2E-C02A5B6E1407 Q37304123-004DC77C-CD0A-4F50-ACA4-0ED8035BA77F Q37354839-60B4C915-8AFD-4DD4-9195-1EB61D0564FB Q37470972-161DAA2A-EBCE-4DE0-B900-E9A174838988 Q37664530-AEEB7736-1079-4777-A323-5AA1FB4FC978 Q37670438-4E0099E1-FDE5-4777-8D4E-D4D3778640E2 Q37676826-0CF8293D-28AF-46A8-A5EB-C58D6C17DDC3 Q37700335-B51D5E3A-4682-4499-BBDD-A3F855AC1574 Q37703980-962423AA-C784-49C4-8DF8-4FCF99D20FE6 Q37883007-F0728624-DA5E-4A98-9758-EC91120E06C2 Q38318645-43B06F52-4F9D-405C-A3D5-8C8CC24C101B Q38348946-6DE8C1C5-265D-4F01-83C4-F9D1FF41DE7E Q38989787-4032FEB4-7337-43E4-9070-A9DA6E0D8A8D

P2860

Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies.

http://www.wikidata.org/entity/Q33295304

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Beta2-microglobulin as a bioma ...... rofiling and clinical studies.

@ast

Beta2-microglobulin as a bioma ...... rofiling and clinical studies.

@en

Beta2-microglobulin as a bioma ...... rofiling and clinical studies.

@nl

type

label

Beta2-microglobulin as a bioma ...... rofiling and clinical studies.

@ast

Beta2-microglobulin as a bioma ...... rofiling and clinical studies.

@en

Beta2-microglobulin as a bioma ...... rofiling and clinical studies.

@nl

prefLabel

Beta2-microglobulin as a bioma ...... rofiling and clinical studies.

@ast

Beta2-microglobulin as a bioma ...... rofiling and clinical studies.

@en

Beta2-microglobulin as a bioma ...... rofiling and clinical studies.

@nl

P1433

Q33295304-A47D55FE-C440-4935-B8C8-845BAE530E78

P1476

Q33295304-A642917D-2299-47E8-8DE4-D2682735A923

P2093

Q33295304-180CFFEE-4315-46F8-A161-B3826B1C1969

Q33295304-19F5183E-B3D1-4DCF-B51E-10567C368DE1

Q33295304-5FF38893-CA76-46F0-A186-529D3C7379AF

Q33295304-783CC8D9-952D-47A1-BF05-D96143DDE73F

Q33295304-7E95D375-A4CD-483F-89C8-E67B99351B59

Q33295304-80A3651F-902F-4BB4-8AE5-8F44BDEE064E

Q33295304-8529C649-A3B5-4FAC-8DA6-4540C3F4DEB2

Q33295304-D5C9D8C0-7282-4F62-8A02-5A6CBC4942A2

Q33295304-E8DEC1F4-356E-4BD3-A877-460437AE60D2

Q33295304-FDCB2CD5-04A6-4DAC-A032-25CF60C9B5DA

P304

Q33295304-8B44C72F-3F65-4E7A-A6C0-435CF42ECE0E

P31

Q33295304-2FE32C9C-552D-410B-A4BD-D316B72F3CEF

P356

Q33295304-CA2737CA-FA48-4454-B8F5-F1736A3358F7

P407

Q33295304-A316B7E4-AFB9-49DB-8695-2CC54946D336

P433

Q33295304-BEE38C4F-E6FA-46FD-B326-6130818757AB

P478

Q33295304-28CC2BFD-7107-458D-94E8-9B121B4F488D

P50

Q33295304-AFA62EB1-1A6C-488A-99FA-15AE07C9D962

P577

Q33295304-D9329C65-1849-4E16-81A2-8DAF474CC7FB

P698

Q33295304-10C9AE38-178F-4C43-872F-3171C362C8DA

P921

Q33295304-A3FDE380-46D2-46E8-A860-1F9D13CB7BD6

P356

CIRCULATIONAHA.106.683722

P1433

P1476

Beta2-microglobulin as a bioma ...... rofiling and clinical studies.

@en

P2093

Andrew M Wilson

http://www.w3.org/2001/XMLSchema#string

Balasubramanian Narasimhan

http://www.w3.org/2001/XMLSchema#string

Eiichiro Kimura

http://www.w3.org/2001/XMLSchema#string

Eric T Fung

http://www.w3.org/2001/XMLSchema#string

Fujun Zhang

http://www.w3.org/2001/XMLSchema#string

Jeffrey W Olin

http://www.w3.org/2001/XMLSchema#string

Kendall R Beck

http://www.w3.org/2001/XMLSchema#string

Nandini Nair

http://www.w3.org/2001/XMLSchema#string

Randall K Harada

http://www.w3.org/2001/XMLSchema#string

Xiao-Ying Meng

http://www.w3.org/2001/XMLSchema#string

P304

1396-1403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.106.683722

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17724262

http://www.w3.org/2001/XMLSchema#string

P921